亿腾嘉和2026年上半年营收8.73亿元，经调整净亏损0.33亿元

公告速递

Aug 28

2026年8月28日，亿腾嘉和发布2026年上半年财报。报告期内，公司实现营收8.73亿元，同比下降23.1%。经调整净亏损从上年同期的经调整净利润1.58亿元转为-0.33亿元，同比下滑120.9%。同期经调整EBITDA为2.05亿元，同比下降52.6%。经营活动产生的现金流量净额达3.37亿元，相比上年同期的2.95亿元增长14.3%，显示出一定的现金流稳健性。

在成本结构方面，研发投入为1.08亿元，同比增长48.2%；销售及分销开支为2.23亿元，同比下降约6%；管理费用为1.16亿元，同比下降约8.5%。报告期内整体毛利率为66.2%，基本与上年同期的66.9%保持平稳。

分业务来看，原研产品板块收入7.77亿元，同比下降24%，其下产品稳可信、希刻劳、亿瑞平等均有不同幅度变化；创新产品板块整体收入1.16亿元，同比上升52.2%，唯思沛实现0.86亿元，汝佳宁贡献0.25亿元，稳可达为0.05亿元。公司表示将继续深耕乳腺癌、心血管等高潜力创新药赛道，并加强双/多抗、抗体偶联药物与小核酸药物研发。

展望下半年，亿腾嘉和计划重点推进核心产品GB268、EDP167等多个项目的研发和临床试验，并加速差异化创新布局，深化大分子生物药与小核酸药物等前沿技术平台，为更多重大疾病提供高附加值的治疗方案。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1129787359"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129787359\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129787359?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-28 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129787359","market":"sh","top_or_hot":-1,"title":"亿腾嘉和2026年上半年营收8.73亿元，经调整净亏损0.33亿元","media":"公告速递","content":"<p>2026年8月28日，亿腾嘉和发布2026年上半年财报。报告期内，公司实现营收8.73亿元，同比下降23.1%。经调整净亏损从上年同期的经调整净利润1.58亿元转为-0.33亿元，同比下滑120.9%。同期经调整EBITDA为2.05亿元，同比下降52.6%。经营活动产生的现金流量净额达3.37亿元，相比上年同期的2.95亿元增长14.3%，显示出一定的现金流稳健性。</p>\n<p>在成本结构方面，研发投入为1.08亿元，同比增长48.2%；销售及分销开支为2.23亿元，同比下降约6%；管理费用为1.16亿元，同比下降约8.5%。报告期内整体毛利率为66.2%，基本与上年同期的66.9%保持平稳。</p>\n<p>分业务来看，原研产品板块收入7.77亿元，同比下降24%，其下产品稳可信、希刻劳、亿瑞平等均有不同幅度变化；创新产品板块整体收入1.16亿元，同比上升52.2%，唯思沛实现0.86亿元，汝佳宁贡献0.25亿元，稳可达为0.05亿元。公司表示将继续深耕乳腺癌、心血管等高潜力创新药赛道，并加强双/多抗、抗体偶联药物与小核酸药物研发。</p>\n<p>展望下半年，亿腾嘉和计划重点推进核心产品GB268、EDP167等多个项目的研发和临床试验，并加速差异化创新布局，深化大分子生物药与小核酸药物等前沿技术平台，为更多重大疾病提供高附加值的治疗方案。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>亿腾嘉和2026年上半年营收8.73亿元，经调整净亏损0.33亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n亿腾嘉和2026年上半年营收8.73亿元，经调整净亏损0.33亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-08-28 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>2026年8月28日，亿腾嘉和发布2026年上半年财报。报告期内，公司实现营收8.73亿元，同比下降23.1%。经调整净亏损从上年同期的经调整净利润1.58亿元转为-0.33亿元，同比下滑120.9%。同期经调整EBITDA为2.05亿元，同比下降52.6%。经营活动产生的现金流量净额达3.37亿元，相比上年同期的2.95亿元增长14.3%，显示出一定的现金流稳健性。</p>\n<p>在成本结构方面，研发投入为1.08亿元，同比增长48.2%；销售及分销开支为2.23亿元，同比下降约6%；管理费用为1.16亿元，同比下降约8.5%。报告期内整体毛利率为66.2%，基本与上年同期的66.9%保持平稳。</p>\n<p>分业务来看，原研产品板块收入7.77亿元，同比下降24%，其下产品稳可信、希刻劳、亿瑞平等均有不同幅度变化；创新产品板块整体收入1.16亿元，同比上升52.2%，唯思沛实现0.86亿元，汝佳宁贡献0.25亿元，稳可达为0.05亿元。公司表示将继续深耕乳腺癌、心血管等高潜力创新药赛道，并加强双/多抗、抗体偶联药物与小核酸药物研发。</p>\n<p>展望下半年，亿腾嘉和计划重点推进核心产品GB268、EDP167等多个项目的研发和临床试验，并加速差异化创新布局，深化大分子生物药与小核酸药物等前沿技术平台，为更多重大疾病提供高附加值的治疗方案。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06998","symbol_name":"亿腾嘉和","start_time":0,"source_url":"","article_id":"1129787359","we_media_id":"1097772564","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129787359","pubTimestamp":1787921334,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"公告速递","introduction":"港美股公告全覆盖","home_visible":1,"id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"2026年8月28日，亿腾嘉和发布2026年上半年财报。报告期内，公司实现营收8.73亿元，同比下降23.1%。经调整净亏损从上年同期的经调整净利润1.58亿元转为-0.33亿元，同比下滑120.9%。经营活动产生的现金流量净额达3.37亿元，相比上年同期的2.95亿元增长14.3%，显示出一定的现金流稳健性。报告期内整体毛利率为66.2%，基本与上年同期的66.9%保持平稳。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06998":"亿腾嘉和"},"translate_title":"Yiteng Jiahe reported revenue of 873 million yuan and an adjusted net loss of 33 million yuan in the first half of 2026.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06998":1},"content_text":"2026年8月28日，亿腾嘉和发布2026年上半年财报。报告期内，公司实现营收8.73亿元，同比下降23.1%。经调整净亏损从上年同期的经调整净利润1.58亿元转为-0.33亿元，同比下滑120.9%。同期经调整EBITDA为2.05亿元，同比下降52.6%。经营活动产生的现金流量净额达3.37亿元，相比上年同期的2.95亿元增长14.3%，显示出一定的现金流稳健性。\n在成本结构方面，研发投入为1.08亿元，同比增长48.2%；销售及分销开支为2.23亿元，同比下降约6%；管理费用为1.16亿元，同比下降约8.5%。报告期内整体毛利率为66.2%，基本与上年同期的66.9%保持平稳。\n分业务来看，原研产品板块收入7.77亿元，同比下降24%，其下产品稳可信、希刻劳、亿瑞平等均有不同幅度变化；创新产品板块整体收入1.16亿元，同比上升52.2%，唯思沛实现0.86亿元，汝佳宁贡献0.25亿元，稳可达为0.05亿元。公司表示将继续深耕乳腺癌、心血管等高潜力创新药赛道，并加强双/多抗、抗体偶联药物与小核酸药物研发。\n展望下半年，亿腾嘉和计划重点推进核心产品GB268、EDP167等多个项目的研发和临床试验，并加速差异化创新布局，深化大分子生物药与小核酸药物等前沿技术平台，为更多重大疾病提供高附加值的治疗方案。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}